HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA anthrax tests confirmed negative

This article was originally published in The Rose Sheet

Executive Summary

Results of confirmatory testing at all FDA buildings were negative for anthrax, the agency announces Nov. 5. Centers for Disease Control & Prevention is "certain" samples initially found to be "presumptive positive" for anthrax bacteria are negative, FDA says. Agency originally revealed "preliminarily positive" anthrax findings in four agency mailrooms in Rockville, Md., as well as the CFSAN headquarters in Washington, D.C., which houses the Office of Cosmetics & Colors (1"The Rose Sheet" Nov. 5, p. 13). CDC bases confirmation for anthrax on three tests - polymerase chain reaction, gamma-phage assay and direct fluorescent antibody...

You may also be interested in...

FDA Cosmetics Office Building Tests “Presumptive Positive” For Anthrax

The Washington, D.C. building that houses FDA's Center for Food Safety & Applied Nutrition, including the Office of Cosmetics & Colors, has tested "presumptive positive" for the presence of anthrax

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts